|Videos|July 24, 2018
Non Transplant Treatments for MDS & Secondary AML
Author(s)Aplastic Anemia, MDS International Foundation
Dr. Toyosi Odenike, University of Chicago and Dr. Eric Padron, H. Lee Moffitt Cancer Center, discuss the highlights of their session on Non-Transplant Treatments for Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.
Advertisement
Dr. Toyosi Odenike, University of Chicago and Dr. Eric Padron, H. Lee Moffitt Cancer Center, discuss the highlights of their session on Non-Transplant Treatments for Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
5 Years of Prostate Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
FDA Withdraws Krazati/Erbitux Approval in KRAS G12C-Mutated Colorectal Cancer
3
FDA Grants Accelerated Approval to Hyrnuo for Certain Patients With HER2-Mutated NSCLC
4
The Oncology Nurse Who Got Me Through 2 Years of Cancer Treatment
5